Where does Carlo Rizzuto work?

Carlo Rizzuto is Managing Director at Versant Ventures and Board director at Nexo Therapeutics, Inc. and Board director at Pep2Tango Therapeutics and Board director at Pandion Therapeutics.

What does Carlo Rizzuto invest in?

Carlo Rizzuto invests in Biotech, Healthtech, Medical Devices.

What check size does Carlo Rizzuto write?

Carlo Rizzuto typically writes checks of $100K – $5M.

What boards does Carlo Rizzuto sit on?

Carlo Rizzuto holds tracked board seats at 858 Therapeutics, Inc., Century Therapeutics, Inc., Graphite Bio, Inc., Jnana Therapeutics Inc., Nexo Therapeutics, Inc., Pandion Therapeutics, Pandion Therapeutics, Pep2Tango Therapeutics.

Where did Carlo Rizzuto go to school?

Carlo Rizzuto studied at Harvard University (PhD, Virology); University of Virginia (BA, Biology); Miller Place High School.

Carlo Rizzuto

Investor

Managing Director at Versant Ventures · Board director at Nexo Therapeutics, Inc. · Board director at Pep2Tango Therapeutics · Board director at Pandion Therapeutics

New York, New York

Writes $100K – $5M checks · typically $1.5M

About

Carlo Rizzuto, a PhD virologist-turned-VC who pioneered and championed epitranscriptomics and backed Gotham Therapeutics early, is a hands-on builder who often serves as acting CEO/CBO to create first-wave biology companies.

Contact· self-published, not guessed

c•••@versantventures.comreveal

Invests in

BiotechHealthtechMedical Devices

Board director at Nexo Therapeutics, Inc.

Intro paths

→

In turn, Carlo can intro founders to Nexo Therapeutics, Inc.'s investors below.

Nexo Therapeutics, Inc.'s investors · 2

New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2022 Versant VenturesSan Francisco · $250K – $5M checks · since 2026

Board director at Pep2Tango Therapeutics

Intro paths

→

In turn, Carlo can intro founders to Pep2Tango Therapeutics's investors below.

Pep2Tango Therapeutics's investors · 1

Versant VenturesSan Francisco · $250K – $5M checks · since 2024

Board director at Pandion Therapeutics

Intro paths

→

In turn, Carlo can intro founders to Pandion Therapeutics's investors below.

Pandion Therapeutics's investors · 3

Access BiotechnologyNew York City · since 2018 Polaris PartnersBoston · $500K – $5M checks · since 2018 Versant VenturesSan Francisco · $250K – $5M checks · since 2018

Co-founders at Pandion Therapeutics

Jo VineyExecutive Officer

Experience

Versant VenturesManaging Directorcurrent2022 — presentNew York, New York, United States
Versant VenturesPartner2012 — 2022New York City Metropolitan Area
Highline TherapeuticsCEO2015 — 2022New York City Metropolitan Area
NovartisGlobal Program Team Director2010 — 2012
Novartis International AGAssistant to the CEO2010
NovartisAssistant to CEO - Pharmaceuticals2009 — 2010
McKinsey & CompanyAssociate Principal2002 — 2008
engeneOSBusiness Development Manager2000 — 2002

Skills & more

Strategy35Strategic Planning14Pharmaceutical Industry65Lifesciences16Medical Devices27Business Strategy19Management Consulting13Product Development5Biotechnology31R&D8Marketing Strategy9Business Planning6

+6 more

Molecular BiologyVenture CapitalDrug DevelopmentBusiness DevelopmentCross-functional Team LeadershipLife Sciences

From Carlo's professional profile.

Deals · 7

Nexo Therapeutics, Inc.Board seat

via Versant Ventures · filed Mar 2026 · $60M raise

Pep2Tango TherapeuticsBoard seat

via Versant Ventures · filed Nov 2024 · $16.7M raise

Jnana Therapeutics Inc.Board seat

via Versant Ventures · filed Jan 2024 · $107M raise

858 Therapeutics, Inc.Board seat

via Versant Ventures · filed May 2021 · $40M raise

Graphite Bio, Inc.Board seat

via Versant Ventures · filed Mar 2021 · $150.7M raise

Century Therapeutics, Inc.Board seat

via Versant Ventures · filed Mar 2021 · $160M raise

Pandion TherapeuticsBoard seat

via Versant Ventures · filed Apr 2020 · $80M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Alex Mayweg

Managing Director at Versant Ventures

Alicia Levey

Venture Partner at Versant Ventures

Andrew Jefferson

Operating Partner at Versant Ventures

Ariel Kantor

Principal at Versant Ventures

Barbara Lubash

Managing Director at Versant Ventures

Beckie Robertson

Venture Advisor at Intuitive Ventures

Brad Bolzon

Chairman, Managing Director at Versant Ventures

Brian Atwood

Managing Director at Versant Ventures

Network6

Alex Mayweg

Managing Director at Versant Ventures

Amir Nashat

Entrepreneur partner at Polaris Partners focused on healthcare investing and portfolio company executive roles

Barbara Lubash

Managing Director at Versant Ventures

Beckie Robertson

Venture Advisor at Intuitive Ventures

Brad Bolzon

Chairman, Managing Director at Versant Ventures

Eli Casdin

Chief Investment Officer and Founder at Casdin Capital

Investors connected to Carlo in public investor directories — a warm-intro map.

Frequently asked questions

Who is Carlo Rizzuto?: Carlo Rizzuto, a PhD virologist-turned-VC who pioneered and championed epitranscriptomics and backed Gotham Therapeutics early, is a hands-on builder who often serves as acting CEO/CBO to create first-wave biology companies.
Where does Carlo Rizzuto work?: Carlo Rizzuto is Managing Director at Versant Ventures and Board director at Nexo Therapeutics, Inc. and Board director at Pep2Tango Therapeutics and Board director at Pandion Therapeutics.
What does Carlo Rizzuto invest in?: Carlo Rizzuto invests in Biotech, Healthtech, Medical Devices.
What check size does Carlo Rizzuto write?: Carlo Rizzuto typically writes checks of $100K – $5M.
What boards does Carlo Rizzuto sit on?: Carlo Rizzuto holds tracked board seats at 858 Therapeutics, Inc., Century Therapeutics, Inc., Graphite Bio, Inc., Jnana Therapeutics Inc., Nexo Therapeutics, Inc., Pandion Therapeutics, Pandion Therapeutics, Pep2Tango Therapeutics.
Where did Carlo Rizzuto go to school?: Carlo Rizzuto studied at Harvard University (PhD, Virology); University of Virginia (BA, Biology); Miller Place High School.